Document is current
Any future updates will be listed below
-
Authors
Olari, Lia-Raluca https://orcid.org/0000-0001-7793-4408
Liu, Sichen https://orcid.org/0009-0006-1023-9076
Arnold, Franziska
Kühlwein, Julia
Gil Miró, Marta
Updahaya, Ajeet Rijal
Stürzel, Christina
Thal, Dietmar Rudolf https://orcid.org/0000-0002-1036-1075
Walther, Paul
Sparrer, Konstantin M. J. https://orcid.org/0000-0002-8682-1779
Danzer, Karin M. https://orcid.org/0000-0003-0133-7046
Münch, Jan https://orcid.org/0000-0001-7316-7141
Kirchhoff, Frank https://orcid.org/0000-0002-7052-2360
- License Information
-
More Information
Article History
Received: 7 May 2024
Accepted: 6 January 2025
First Online: 18 January 2025
Competing interests
: DRT collaborated with Novartis Pharma AG (Basel, Switzerland), Probiodrug (Halle (Saale), Germany), GE Healthcare (Amersham, UK), and Janssen Pharmaceutical Companies (Beerse, Belgium). JM and FK are inventors on patents for using peptide nanofibrils to enhance viral transduction. Remaining authors report no competing interests.
